The allograft offers a protective environment or covering for repair of the cornea and conjunctiva. Credit: 4 PM production / Shutterstock.com.

NovaBay Pharmaceuticals has commercially introduced its optic Avenova Allograft for eyecare professionals in the US.

Available through the company’s physician-dispensed channel, the optic allograft can be used as a protective covering during the repair of ocular surfaces.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is claimed to be the only optic allograft produced utilising the patented six-step BioREtain process from BioStem Technologies.

This process helps protect the natural integrity of the placental tissue. BioStem will handle the manufacturing, packaging, shipping and regulatory compliance of the allograft.

The allograft offers a protective environment or covering to repair the cornea and conjunctiva, enabling the ocular surface to return to a healthier state.

See Also:

Measuring between 20 and 50μ thick, the allograft features the amnion layer of the placental membrane and is suitable for delicate ophthalmic applications. It is available in 8mm, 10mm and 12mm diameter sizes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This product launch follows a previous agreement in which NovaBay secured the right to market BioStem’s Amniotic Tissue Allograft under the Avenova brand.

NovaBay CEO and General Counsel Justin Hall said: “Avenova Allograft is a valuable addition to our high-quality, differentiated eyecare franchise and allows us to provide another solution for the professionals who specialise in treating eye conditions.

“We have fostered strong relationships with eyecare professionals nationwide, including thousands of optometrists and ophthalmologists who recommend, prescribe and sell Avenova-branded products every day. Sales in our physician-dispensed channel continue to grow, providing us with a terrific platform to launch this innovative product.”